Affinity Asset Advisors LLC boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 150.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company’s stock after acquiring an additional 15,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Axsome Therapeutics were worth $1,687,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Axsome Therapeutics by 0.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,614,145 shares of the company’s stock valued at $176,350,000 after purchasing an additional 10,405 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Axsome Therapeutics by 1.8% during the 1st quarter. BlackRock Inc. now owns 2,319,793 shares of the company’s stock worth $131,346,000 after acquiring an additional 40,027 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Axsome Therapeutics by 3.1% in the second quarter. Geode Capital Management LLC now owns 483,250 shares of the company’s stock valued at $32,600,000 after purchasing an additional 14,663 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at $23,747,000. Finally, FMR LLC lifted its holdings in shares of Axsome Therapeutics by 4.0% in the second quarter. FMR LLC now owns 350,535 shares of the company’s stock valued at $23,647,000 after purchasing an additional 13,524 shares in the last quarter. Hedge funds and other institutional investors own 59.00% of the company’s stock.
AXSM has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 target price for the company in a report on Wednesday, August 4th. Truist cut their price objective on Axsome Therapeutics from $200.00 to $160.00 and set a “buy” rating for the company in a report on Tuesday, August 10th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, September 15th. William Blair reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Friday, August 27th. Finally, SVB Leerink cut their price objective on Axsome Therapeutics from $115.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, August 10th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $102.48.
Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Sunday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.02. As a group, analysts anticipate that Axsome Therapeutics, Inc. will post -3.62 EPS for the current year.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Recommended Story: After-Hours Trading
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.